Summary The SARS-CoV-2 pandemic has affected more than 185 million people worldwide resulting in over 4 million deaths. To contain the pandemic, there is a continued need for safe vaccines that provide durable protection at low and scalable doses and can be deployed easily. Here, AAVCOVID-1, an adeno-associated viral (AAV), spike-gene-based vaccine candidate demonstrates potent immunogenicity in mouse and non-human primates following a single injection and confers complete protection from SARS-CoV-2 challenge in macaques. Peak neutralizing antibody titers are sustained at 1 year and complemented by functional memory T cell responses. The AAVCOVID vector has no relevant pre-existing immunity in humans and does not elicit cross-reactivity to common AAVs used in gene therapy. Vector genome persistence and expression wanes following injection. The single low-dose requirement, high-yield manufacturability, and 1-month stability for storage at room temperature may make this technology well suited to support effective immunization campaigns for emerging pathogens on a global scale. Graphical abstract Highlights • AAVCOVID is a gene- and AAV-based spike antigen COVID-19 vaccine • A single AAVCOVID dose provides protection from SARS-CoV-2 challenge in monkeys • Neutralizing antibody levels in animals are maintained at peak for a year • AAVCOVID can be produced at scale and stored at room temperature for 1 month Zabaleta et al. report AAVCOVID, an experimental preventative vaccine for COVID-19. AAVCOVID is a vaccine that delivers the SARS-CoV-2 spike antigen as a gene via an adeno-associated vector. Results demonstrate protection from viral challenge in NHPs, durable immunogenicity, cross-reactivity with emerging variants, a scalable production method, and room-temperature stability for 1 month.
【저자키워드】 COVID-19, SARS-CoV-2, Vaccine, immunization, Durability, single dose, AAV, adeno-associated virus, room-temperature stable, viral challenge, 【초록키워드】 COVID-19 vaccine, pandemic, antibody, SARS-CoV-2 pandemic, Human, Genome, variants, memory, Antigen, Gene therapy, cross-reactivity, stability, pathogen, persistence, NHPs, vector, low-dose, vaccine candidate, temperature, non-human primate, expression, pre-existing immunity, Neutralizing antibody titer, macaques, dose, deaths, Safe, Support, Abstract, injection, Complete, responses, peak, effective, Result, produced, resulting, affected, functional, provide, elicit, sustained, the SARS-CoV-2, vaccine for COVID-19, 【제목키워드】 COVID-19 vaccine, non-human primate, provide,